SpyGlass Pharma, Inc. (SGP) Stock Profile — Insider Trades & Financials

EPS$-17.98

Market Cap$742.7M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Patrick Mooney

CEO & Executive Director

SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), which comprises novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was incorporated in 2019 and is based in Aliso Viejo, California.

Founded: 2019
Employees: 32
Headquarters

⚡

Core Efficiency

D/E Ratio?

-0.10

📊

Profitability Ratios

Current Ratio?

12.67

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 25, 2026 (in 138 days)

Annual Report (10-K) — Estimated

Aug 25, 2026

Predicted10-K

Mar 26, 2026

10-KQ4 202525d after period end

Mar 26, 2026

10-KFY 202585d after period end

Data Freshness

Financial Data

3 days ago

Latest filing: 2026-03-26

SEC Metadata

17 days ago